Clearside rises on positive data from early-stage eye disorder drug trial

Clearside Biomedical,

16/10/2023 13:37

** Shares of drug developer Clearside Biomedical  CLSD.O 
rise 6.8% to 91 cents premarket
    ** Co says its experimental drug for wet AMD met the safety
profile without any adverse events in an early-stage study 
    ** Wet AMD is an eye disorder that causes blurred vision or
a blind spot in the central vision
    ** Up to last close, shares down 23.1% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))